1. The potential use of ABO blood group system for risk stratification of COVID-19
- Author
-
Sayid Maalim, Elaria Yacoub, Alaa Saud, Abdel Fattah Taha, Salma Gad, Sara Salama, Bishoy Kamel, Aliaa Osman, Rahma Menshawey, Nouran Hegazy, Raghda Fouda, Nadine El-Husseiny, Osama Saad, Marina Saad, Noura Shebl, Sandra Sherien, Maria Dous, Mario Zaghar, Omar Khalid, Reham Mahrous, Reem J. Husseiny, Youstina Aziz, Sarah Ismail, Mariam Abdelaziz, Esraa Menshawey, Nourhan Fahmy, Antoine Fakhry AbdelMassih, Habiba Allah Ismail, Lina Aita, Sajjad Ali, Peter Afdal, and Yara ElHefnawi
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Autoimmunity ,medicine.disease_cause ,Risk Assessment ,Antibodies ,Article ,ABO Blood-Group System ,COVID-19 Serological Testing ,Hypercoagulability ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,ABO blood group system ,medicine ,Humans ,Obesity ,Pandemics ,COVID-19 Serotherapy ,Furin ,biology ,business.industry ,Microbiota ,Immunization, Passive ,ABO blood group ,COVID-19 ,Thrombosis ,General Medicine ,Immune dysregulation ,medicine.disease ,Gastrointestinal Microbiome ,030104 developmental biology ,Risk stratification ,Disease Progression ,biology.protein ,Female ,Antibody ,business ,Dysbiosis ,030217 neurology & neurosurgery - Abstract
ABO blood groups is a cheap and affordable test that can be immediately retrieved from COVID-19 patients at the diagnosis. There is increasing evidence that non-O blood groups have both higher susceptibility and higher severity of COVID-19 infections. The reason behind such relationship seems elusive. Regarding susceptibility, Non-O individuals have Anti-A antibodies which can prevent viral entry across ACE-2 receptors, moreover, Non-O individuals are at higher risk of autoimmunity, hypercoagulable state, and dysbiosis resulting in an augmented tendency for vascular inflammatory sequelae of COVID-19. We can conclude, on the diagnostic level, that ABO blood groups can be potentially used for risk stratification of affected COVID-19 patients, to anticipate the deterioration of patients at higher risk for complications. On a therapeutic level, plasma from normal O blood group individuals might potentially replace the use of convalescent serum for the treatment of COVID-19.
- Published
- 2020
- Full Text
- View/download PDF